Putnam Investments’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Putnam Investments’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-92,877	Closed	-$1.03M	–	1230
2023 Q2	$1.03M	Sell	92,877 -36,510	-28%	-$509K	﹤0.01%	840
2023 Q1	$1.74M	Buy	129,387 +95,151	+278%	+$1.65M	﹤0.01%	757
2022 Q4	$423K	Buy	34,236 +2,491	+8%	+$35.3K	﹤0.01%	970
2022 Q3	$443K	Buy	31,745 +2,791	+10%	+$44.9K	﹤0.01%	960
2022 Q2	$400K	Sell	28,954 -356	-1%	-$5.7K	﹤0.01%	991
2022 Q1	$477K	Sell	29,310 -2,090	-7%	-$32.7K	﹤0.01%	1009
2021 Q4	$511K	Buy	+31,400	New	+$529K	﹤0.01%	1008
2019 Q3	–	Sell	-19,703	Closed	-$1.57M	–	949
2019 Q2	$1.57M	Buy	19,703 +6,573	+50%	+$588K	﹤0.01%	745
2019 Q1	$1.47M	Buy	+13,130	New	+$1.43M	﹤0.01%	734
2014 Q2	–	Sell	-5,174	Closed	-$1.71M	–	1518
2014 Q1	$1.71M	Buy	+5,174	New	+$1.75M	﹤0.01%	1081

Other funds holding ICPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Putnam Investments's ICPT Position: Q3 2023 in Review

Putnam Investments sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 92,877 shares — an estimated $1.03M sold.

Putnam Investments first reported a position in ICPT in Q1 2014 and held it in 10 quarters. The position peaked at $1.74M in Q1 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

Putnam Investments reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Putnam Investments sold 92,877 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.03M.
Putnam Investments first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 10 quarters.
Putnam Investments's Intercept Pharmaceuticals, Inc. position peaked at $1.74M in Q1 2023.
146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Putnam Investments's 13F filing for Q3 2023, filed 14 Nov 2023.